Results 191 to 200 of about 5,266 (226)

Abstract WP16: ROLE OF EPTIFIBATIDE IN POST-THROMBECTOMY STENOSIS

Stroke
Introduction: Currently, no level A evidence exists for the optimal rescue strategy for cases at high risk for re-occlusion following endovascular thrombectomy (EVT) in acute ischemic stroke.
Sivani Lingam, William Liu, Sabriya Sowers, Margaret Houghton, Laith N Maali   +4 more
semanticscholar   +1 more source

Severe thrombocytopenia possibly related to readministration of eptifibatide

Catheterization and Cardiovascular Interventions, 2001
AbstractThrombocytopenia following eptifibatide therapy is a rare event, and acute severe thrombocytopenia following readministration has not been reported. We describe a case of acute severe thrombocytopenia following reexposure to eptifibatide during percutaneous coronary intervention.
Susan Hurden, Fran L. Paradiso-Hardy, Mina Madan, Sam Radhakrishnan, Eric A. Cohen   +4 more
openaire   +3 more sources

Intracoronary delivery of eptifibatide with the ClearWay® RX infusion catheter

Catheterization and Cardiovascular Interventions, 2011
AbstractAcute coronary syndromes are caused by plaque rupture and the formation of an occlusive thrombus. Intracoronary (IC) bolus administration of eptifibatide may result in higher levels of platelet glycoprotein IIb/IIIa (GP IIb/IIIa) receptor occupancy (RO) in the local coronary bed, disaggregate thrombus in the epicardial artery, and ...
C. Michael Gibson, Albert J. Deibele
openaire   +3 more sources

Impact of computerized dosing on eptifibatide-associated bleeding and mortality

American Heart Journal, 2009
The study aimed to determine the impact on eptifibatide-associated bleeding by implementing a computerized dosing algorithm in the cardiac catheterization suite.Excessive dosing of eptifibatide is associated with increased bleeding rates and hospital mortality. Although dosing adjustments based on renal function has been recommended, its implementation
John M. Buergler, David Putney, Robert E. Fromm, Neal S. Kleiman   +3 more
openaire   +3 more sources

Eptifibatide

Reactions weekly, 2023

semanticscholar   +1 more source

Clinical Evaluation of the Tolerability, Pharmacokinetics, and Inhibition of Platelet Aggregation of Eptifibatide in Healthy Chinese Subjects

Clinical pharmacology in drug development, 2019
The present study aimed to evaluate the pharmacokinetic properties and antiplatelet aggregation activity of eptifibatide in healthy Chinese subjects. Eptifibatide (180 μg/kg) was administrated by 2 bolus injections 10 minutes apart, followed by a 2.0 μg ...
Li Liu, Yanhua Ding, Z. Jiao, Min Wu, Cuiyun Li, Jingrui Liu, Chengjiao Liu, Yue Hu, Qingmei Li, Hong Zhang   +9 more
semanticscholar   +1 more source

Eptifibatide-Induced Thrombocytopenia—When Inhibitor Turns Killer

American Journal of Therapeutics, 2016
Eptifibatide is a commonly and widely used drug for management of acute coronary syndrome and during percutaneous coronary intervention. It is usually well tolerated with no major adverse effects. We report a rare case of life-threatening thrombocytopenia secondary to eptifibatide along with a literature review of available evidence.
Abhishek Deshmukh, Zufeng Ding, Yao Dai, Thomas E. Watts, Naga Venkata Pothineni   +4 more
openaire   +3 more sources

Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta‐analysis

Journal of Evidence-Based Medicine, 2017
Glycoprotein IIb/IIIa inhibitors were the strongest available antiplatelet therapy and have been shown to reduce cardiac ischemic complications in patients undergoing percutaneous coronary intervention.
Xiaoqin Zhou, Xinyu Wu, Huan Sun, Jing Li   +3 more
semanticscholar   +1 more source

Characterization of eptifibatide during drug formulation stability assays

Journal of Pharmaceutical and Biomedical Analysis, 2003
The objective of the study was to determine the identity of a new impurity detected in HPLC chromatograms of research samples of eptifibatide manufactured by a new process and formulated into drug product. The identification of the unknown impurity was required in order to understand the mechanism of its formation.
Ronghua Wang, Debby Feder, Frank Y. Hsieh   +2 more
openaire   +3 more sources

Comparing efficacy of receiving different dosages of eptifibatide in bleeding after percutaneous coronary intervention in patients with myocardial infarction

ARYA Atherosclerosis, 2019
BACKGROUND Acute coronary syndrome (ACS) is a common condition that needs appropriate treatment like percutaneous coronary intervention (PCI). Glycoprotein IIb/IIIa inhibitors (GPI) like eptifibatide prevent procedural ischemic complications after PCI ...
H. Shemirani, A. Khosravi, A. Eghbal, A. Amirpour, Farshad Roghani, Seyed Mohammad Hashemi-Jazi, A. Pourmoghaddas, R. Heidari, A. Sajjadieh, N. Sadeghi, H. Sanei   +10 more
semanticscholar   +1 more source